Laurence Elias

4.5k total citations · 1 hit paper
72 papers, 3.2k citations indexed

About

Laurence Elias is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Laurence Elias has authored 72 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 27 papers in Hematology and 17 papers in Genetics. Recurrent topics in Laurence Elias's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (13 papers) and Acute Myeloid Leukemia Research (12 papers). Laurence Elias is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (13 papers) and Acute Myeloid Leukemia Research (12 papers). Laurence Elias collaborates with scholars based in United States, Netherlands and Canada. Laurence Elias's co-authors include Joseph J. Buggy, Frederick R. Appelbaum, R. Kanti, Bercedis L. Peterson, Charles A. Schiffer, Richard A. Larson, Lois E. Shepherd, John Hines, Jonathan E. Kolitz and Salvatore F. Pietromonaco and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Laurence Elias

71 papers receiving 3.1k citations

Hit Papers

Fludarabine Compared with... 2000 2026 2008 2017 2000 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
    2000 754 citations R. Kanti, Bercedis L. Peterson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laurence Elias United States 26 1.4k 1.2k 914 896 806 72 3.2k
Leslie A. Andritsos United States 30 2.1k 1.4× 1.5k 1.2× 967 1.1× 1.1k 1.2× 1.0k 1.3× 161 3.5k
José A. Martínez-Climent Spain 39 865 0.6× 1.0k 0.8× 1.9k 2.1× 509 0.6× 1.3k 1.6× 135 4.5k
Alexander Egle Austria 35 1.2k 0.8× 903 0.7× 2.0k 2.1× 1.2k 1.3× 1.5k 1.8× 153 4.2k
Paris S. Mitrou Germany 28 757 0.5× 1.1k 0.9× 570 0.6× 491 0.5× 939 1.2× 92 2.3k
Sari H. Enschede United States 19 1.7k 1.2× 1.3k 1.0× 2.1k 2.3× 717 0.8× 1.2k 1.4× 46 4.0k
Walter E. Aulitzky Germany 34 692 0.5× 420 0.3× 1.4k 1.5× 502 0.6× 1.1k 1.3× 121 3.6k
Sarit Assouline Canada 30 1.5k 1.0× 2.2k 1.7× 1.2k 1.3× 835 0.9× 2.2k 2.7× 164 4.5k
Y. Lynn Wang United States 35 1.8k 1.2× 960 0.8× 1.5k 1.7× 600 0.7× 551 0.7× 116 3.5k
M Stetler-Stevenson United States 22 430 0.3× 677 0.5× 680 0.7× 735 0.8× 869 1.1× 44 2.3k
Sergej Konoplev United States 35 1.2k 0.9× 964 0.8× 1.4k 1.5× 1.1k 1.2× 1.4k 1.7× 154 4.6k

Countries citing papers authored by Laurence Elias

Since Specialization
Citations

This map shows the geographic impact of Laurence Elias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Elias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Elias more than expected).

Fields of papers citing papers by Laurence Elias

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Elias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Elias. The network helps show where Laurence Elias may publish in the future.

Co-authorship network of co-authors of Laurence Elias

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Elias. A scholar is included among the top collaborators of Laurence Elias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Elias. Laurence Elias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Xiaoqiang, et al.. (2024). EP.08A.03 Real World Outcomes of Adjuvant Atezolizumab in NSCLC: A Single Institution Study. Journal of Thoracic Oncology. 19(10). S564–S565.
2.
Richardson, Paul G., William Bensinger, Carol Ann Huff, et al.. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology. 180(6). 821–830. 30 indexed citations
3.
Massó-Vallés, Daniel, Toni Jauset, Erika Serrano, et al.. (2015). Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma. Cancer Research. 75(8). 1675–1681. 92 indexed citations
4.
Chang, Betty, Michelle Francesco, Martin F. M. de Rooij, et al.. (2013). Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 122(14). 2412–2424. 159 indexed citations
5.
Elias, Laurence, Jun Chen, & Joseph J. Buggy. (2013). Abstract C258: BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase.. Molecular Cancer Therapeutics. 12(11_Supplement). C258–C258. 1 indexed citations
6.
Buggy, Joseph J. & Laurence Elias. (2012). Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy. International Reviews of Immunology. 31(2). 119–132. 172 indexed citations
7.
Ratain, Mark J., Elisabeth I. Heath, Amy Weise, et al.. (2009). Abstract C169: Intermittent dosing of Imetelstat Sodium, a telomerase inhibitor, induces drug exposure consistent with in vivo tumor growth inhibition. Molecular Cancer Therapeutics. 8(12_Supplement). C169–C169. 1 indexed citations
8.
9.
10.
Kanti, R., Bercedis L. Peterson, Frederick R. Appelbaum, et al.. (2000). Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine. 343(24). 1750–1757. 754 indexed citations breakdown →
11.
Elias, Laurence, et al.. (1998). Two unique 5′ untranslated regions in mRNAs encoding human 14-3-3ζ: differential expression in hemopoietic cells. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1395(3). 281–287. 3 indexed citations
12.
Pietromonaco, Salvatore F., Peter C. Simons, Amnon Altman, & Laurence Elias. (1998). Protein Kinase C-θ Phosphorylation of Moesin in the Actin-binding Sequence. Journal of Biological Chemistry. 273(13). 7594–7603. 184 indexed citations
13.
Simons, Peter C., Salvatore F. Pietromonaco, David Reczek, Anthony Bretscher, & Laurence Elias. (1998). C-Terminal Threonine Phosphorylation Activates ERM Proteins to Link the Cell's Cortical Lipid Bilayer to the Cytoskeleton. Biochemical and Biophysical Research Communications. 253(3). 561–565. 119 indexed citations
14.
Elias, Laurence, Donna Stock-Novack, David R. Head, et al.. (1993). A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.. PubMed. 7(3). 361–5. 55 indexed citations
15.
Elias, Laurence. (1988). Stimulation by tumor necrosis factor of HL‐60 thymidine salvage pathway metabolism dissociated from proliferation. Journal of Cellular Physiology. 136(1). 95–102. 7 indexed citations
16.
Elias, Laurence, et al.. (1987). A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.. PubMed. 1(2). 105–10. 39 indexed citations
17.
Elias, Laurence, et al.. (1987). A trial of recombinant alpha 2 interferon in the myelodysplastic syndrome: II. Characterization and response of granulocyte and platelet dysfunction.. PubMed. 1(2). 111–5. 5 indexed citations
18.
Elias, Laurence, et al.. (1980). Altered pattern of differentiation and proliferation of HL-60 promyelocytic leukemia cells in the presence of leucocyte conditioned medium. Leukemia Research. 4(3). 301–307. 58 indexed citations
19.
Elias, Laurence, Carol S. Portlock, & Saul A. Rosenberg. (1978). Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer. 42(4). 1705–1710. 99 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leslie A. Andritsos Breakdown of academic impact, for papers by José A. Martínez-Climent Breakdown of academic impact, for papers by Alexander Egle Breakdown of academic impact, for papers by Paris S. Mitrou Breakdown of academic impact, for papers by Sari H. Enschede Breakdown of academic impact, for papers by Walter E. Aulitzky Breakdown of academic impact, for papers by Sarit Assouline Breakdown of academic impact, for papers by Y. Lynn Wang Breakdown of academic impact, for papers by M Stetler-Stevenson Breakdown of academic impact, for papers by Sergej Konoplev
Rankless by CCL
2026